Skip to content

A weight loss trial of Weight Watchers groups with additional dietetic support compared to regular Weight Watchers groups only in women treated for breast cancer

A randomised feasibility trial of Weight Watchers groups with additional dietetic support compared to Weight Watchers groups only in women treated for breast cancer: The BReast cancer healthy weIGHT (BRIGHT) study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN29623418
Enrollment
90
Registered
2013-11-12
Start date
2013-10-10
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and breast cancer Cancer Obesity, Malignant neoplasm of breast

Interventions

A mixed method randomised feasibility intervention study for a proposed 12 week randomised controlled trial. A total of 90 participants (30 per group) will be allocated to one of three groups:

Sponsors

University of Aberdeen
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women who have completed initial treatment (surgery, chemotherapy and/or radiotherapy) for breast cancer 2. Age at least 18 years 3. Body mass index greater than or equal to 25

Exclusion criteria

Exclusion criteria: 1. Known distant metastasis prior to study entry 2. Currently participating in any supervised weight loss programmes 3. Participated in Weight Watchers programme within the previous three months 4. Pregnant women 5. Diagnosed eating disorder 6. Need interpreter to understand English

Design outcomes

Primary

MeasureTime frame
The feasibility and acceptability of the intervention will be measured from the beginning till trial exit and evaluated by examining data on recruitment rate, attendance at intervention sessions, drop-out rates, completion rates and participant feedback from semi-structured interviews.

Secondary

MeasureTime frame
1. Changes in body weight. It will be measured at the baseline visit and trial end-point visit 2. Quality of life (QoL). Participants will complete this questionnaire at the baseline visit and trial end-point visit

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026